Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04482478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 30, 2025 to Dec 30, 2026
    • Site contact updated
    v6
  2. Study completion date: Dec 30, 2024 to Dec 30, 2025
    • Site contact updated
    v5
  3. Primary completion date: Sep 30, 2023 to Sep 30, 2024
    • Study completion date: Jul 30, 2024 to Dec 30, 2024
    v4
  4. Primary completion date: Sep 30, 2022 to Sep 30, 2023
    • Study completion date: Sep 30, 2022 to Jul 30, 2024
    v3
  5. Primary completion date: Aug 31, 2021 to Sep 30, 2022
    • Study completion date: Nov 30, 2021 to Sep 30, 2022
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial was designed to evaluate the functional and safety effects on dyspeptic symptoms compared to the placebo when ingested with EDL (Extract of Dolichos lablab Linne) in adults who complain of dyspeptic symptoms.
Trial Details
NCT Number NCT04482478
Lead Sponsor Seoul National University Bundang Hospital
Conditions
(from sponsor)		 Functional Dyspepsia
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov